KLBF – Received Anemia Drug approval in Indonesia

KLBF – Received Anemia Drug approval in Indonesia Kalbe Farma (KLBF), through its subsidiary Kalbe-Genexine Biologics (KGbio), has received regulatory approval from the Indonesian Food and Drug Authority (BPOM) for its domestically developed anemia drug, Efepoetin Alfa. This medication, also known as EPO-HyFc (GXE4) designed for anemic patients with chronic kidney disease, offers advantages such as less frequent injections, making it more cost-effective. KG Bio's clinical trials have demonstrated its safety and efficacy, and the potential market for this drug is substantial in Indonesia. The drug has gone through phase 3 clinical trials in multiple countries and will be marketed in Southeast Asia, Central Africa, and Europe. Further, the company plan for the drug's launch in various Asian countries and an expanded scope to include dialysis patients. (Source : Investor Daily)